In addition, the use of half-life-extended IL-2 muteins and antigen therapy could also be applicable to other immune-related diseases that require the tolerance promoted by activated Tregs, such as organ transplant rejection (62, 63) and autoimmune and allergic diseases where the antigens promoting the immune-mediated pathology are known (64–67). This evidence concerns the gene IL2 and allergic disease.